Aptose Biosciences Inc.
Aptose Biosciences Inc. (APS.TO) Stock Forecast & Analyst Price Target
Wall Street consensus, 12-month price targets, model projections, and EPS/revenue estimates — from analyst data and price history.
aps.to · stock forecast · 11 analysts (3M) · FMP · updated Jun 8, 2026
Analyst Rating & Consensus
Based on 11 Wall Street analysts in the past 3 months
Buy
11 analysts
consensus
Rating Breakdown
12-Month Price Target
High
$0.00
Consensus
$0.00
+0.0% upside
Low
$0.00
Median: $0 · Last Close: $2.20
Short-Term Price Prediction
Algorithmically generated · Updated daily
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $2.15 | ↓ 2.31% |
1-day model range: $2.13–$2.16. Peak: $2.16 (-2.31%).
Long-Term Stock Price Prediction
Stock Forecast Based on Technical Analysis
14 TA signals (SMA×6 + EMA×6 + RSI + MACD) · EEAT method transparency
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · APS.TO · Jun 9, 2026
Latest Analyst Ratings & Upgrades
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2025-03-28 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-02-12 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2025-01-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-10 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-12-03 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2024-11-20 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-11 | HC Wainwright & Co. | Maintains | Buy→Buy |
| 2023-08-11 | RBC Capital | Maintains | Outperform→Outperform |
| 2023-08-11 | Piper Sandler | Maintains | Overweight→Overweight |
| 2023-08-11 | Oppenheimer | Maintains | Outperform→Outperform |
Wall Street analysts have recently issued updated ratings on Aptose Biosciences Inc. (APS.TO) stock. Of the recent 34 rating actions, 2 were upgrades and 0 were downgrades. 11 analysts currently cover APS.TO.
Analyst Recommendation Trends
APS.TO analyst recommendation trends show decreasing buy-side sentiment over the past 6 months. Buy rating actions changed from 4 to 1 per month.
Financial Forecast: EPS & Revenue Estimates
Revenue This Year
$0M
Revenue Next Year
$1M
EPS This Year
$-42.84
EPS Next Year
$-9.20
↓ 78.5% YoY
EPS ForecastReported vs Estimated
Analysts forecast APS.TO EPS of $-42.84 for the current fiscal year, based on estimates from 2 analysts. The APS.TO revenue forecast is $0M for the current year. These are analyst consensus estimates via FMP / S&P Global.
About Forecast & Price Prediction
The APS.TO stock forecast is supported by two independent data sources: analyst consensus ratings from 11 Wall Street analysts (S&P Global / FMP), and technical analysis calculated from historical EOD price data. The consensus APS.TO price target is $0.00 (+0.0% upside), with an analyst consensus of Buy.
The APS.TO short-term stock prediction for tomorrow is $2.15 (-2.31%).
Aptose Biosciences Inc. trades on TSX under the ticker APS.TO. The APS.TO stock outlook for 2027 is broadly positive, supported by a Buy consensus among 91% of covering analysts.
Frequently asked questions
APS.TO forecast · 8 questionsAccording to 11 Wall Street analysts, the average 12-month APS.TO price target is $0.00, with a high forecast of $0.00 and a low of $0.00. The median price target is shown in the chart above when available. This implies +0.0% potential upside from the current price of $2.20.
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.